nVerses Capital’s Biogen BIIB Stock Holding History

nVerses Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,000	Closed	-$388K	–	112
2024 Q3	$388K	Buy	+2,000	New	+$418K	0.18%	180

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

nVerses Capital's BIIB Position: Q4 2024 in Review

nVerses Capital sold out of Biogen (BIIB) in Q4 2024, closing a stake of 2,000 shares — an estimated $388K sold.

nVerses Capital first reported a position in BIIB in Q3 2024 and held it in 1 quarter. The position peaked at $388K in Q3 2024. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

nVerses Capital reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 2,000 Biogen shares in Q4 2024, an estimated $388K.
nVerses Capital first reported a position in Biogen in Q3 2024 and held it in 1 quarter.
nVerses Capital's Biogen position peaked at $388K in Q3 2024.
876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.